


Supplementary Figure Legends


Supplementary Figure 1. Progression-free survival in treatment subgroups by first-line therapy in the ASCT-intent subgroup: (A) triplet therapy (VRd, CVd, CTd, or VTd); (B) bortezomib-only with no IMiD (CVd or Vd); (C) doublet therapy (Rd, Td, or Vd); (D) VRd; and (E) IMiD-only therapy (Rd or Td).

Supplementary Figure 1.


A




B



C



D



E

